ESTRO 2024 - Abstract Book

S1898

Clinical - Mixed sites, palliation

ESTRO 2024

statistically significant difference (p: 0.001) for LC rates was found between synchronous oligometastatic patients, metachronous ones, repeated ones and induced ones (100%, 74.3%, 60.6%, and 83.1% at one year, respectively).

Table 1. Patients characteristics

Comorbidities Cardiopathy

40 (61.5%)

Polmunary

4 (6.2%)

Diabetes

11 (16.8%)

Liver

2 (3.1%)

Kidney

4 (6.2%)

Other Tumour

4 (6.2%)

Histology Colorectal

55 (36.7%)

Breast

25 (16.7)

Lung

9 (6.0%)

Ovary

11 (7.3%)

Cervix

1 (0.5%)

Pancreas

21 (14.0%)

H&N

4 (2.7%)

Stomach

2 (1.4%)

Melanoma

9 (6.0%)

Other

13 (8.7%)

Liver Segment S1

1 (0.5%)

S2

9 (6.0%)

S3

3 (2.0%)

S4

18 (12.0%)

S5

15 (10.0%)

S6

21 (14.0%)

S7

9 (6.0%)

S8

20 (13.3%)

>1 Segment

59 (36.2%)

Oligometastases Status* Synchronus Oligometastatic Disease 16 (10.7%) Metacronus Oligorecurrence 15 (10.0%) Metacronus Oligoprogression 15 (10.0%) Repeat Oligorecurrence 15 (10.0%) Repeat Oligopersistant 8 (5.3%) Repeat Oligoprogression 19 (12.7%)